Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles by Siri Tveito et al.
RESEARCH ARTICLE Open Access
Analysis of EpCAM positive cells isolated from
sentinel lymph nodes of breast cancer patients
identifies subpopulations of cells with distinct
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Abstract
Introduction: The presence of tumor cells in the axillary lymph nodes is the most important prognostic factor in
early stage breast cancer. However, the optimal method for sentinel lymph node (SLN) examination is still sought
and currently many different protocols are employed. To examine two approaches for tumor cell detection we
performed, in sequence, immunomagnetic enrichment and RT-PCR analysis on SLN samples from early stage breast
cancer patients. This allowed us to compare findings based on the expression of cell surface proteins with those
based on detection of intracellular transcripts.
Methods: Enrichment of EpCAM and Mucin 1 expressing cells from fresh SLN samples was achieved using
magnetic beads coated with the appropriate antibodies. All resulting cell fractions were analyzed by RT-PCR using
four chosen breast epithelial markers (hMAM, AGR2, SBEM, TFF1). Gene expression was further analyzed using
RT-PCR arrays and markers for epithelial to mesenchymal transition (EMT).
Results: Both EpCAM and Mucin 1 enriched for the epithelial-marker expressing cells. However, EpCAM-IMS
identified epithelial cells in 71 SLNs, whereas only 35 samples were positive with RT-PCR targeting breast epithelial
transcripts. Further analysis of EpCAM positive but RT-PCR negative cell fractions showed that they had increased
expression of MMPs, repressors of E-cadherin, SPARC and vimentin, all transcripts associated with the process of
epithelial to mesenchymal transition.
Conclusions: The EpCAM IMS-assay detected tumor cells with epithelial and mesenchymal-like characteristics, thus
proving to be a more robust marker than pure epithelial derived biomarkers. This finding has clinical implications,
as most methods for SLN analysis today rely on the detection of epithelial transcripts or proteins.
Introduction
The presence of metastatic deposits in the axillary lymph
nodes is the most powerful predictor of survival in early
stage breast cancer patients [1-3]. The sentinel lymph
node (SLN) is defined as the first node or group of nodes
receiving lymph from a tumor area, and the status of the
SLN has been shown to reflect the presence of metastases
in the axillary lymph nodes [4,5]. Reliable detection of
micrometastatic cells in the SLN is, therefore, a subject
of great clinical interest, and several different protocols
aimed at identifying breast epithelial cells within the lym-
phatic basin are currently in use. Metastatic cells may
exist in low concentrations, making their identification
and isolation a difficult task. Studies have shown that
extensive re-examination of presumably negative nodes
will identify more positive specimens, but techniques
using tissue sections are labor intensive if more detailed
analysis is warranted [6-9]. However, several recent
papers have concluded that even small cell deposits may
be of clinical relevance, suggesting that a comprehensive
examination would be worthwhile [10-13].
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Our laboratory has for many years worked with immu-
nomagnetic selection (IMS) using paramagnetic beads
coated with antibodies against cell surface proteins for
positive selection of tumor cells from cell suspensions
[14-16]. The method is fast, sensitive and allows further
molecular characterization of isolated live cells [17]. The
choice of antibodies is decisive for the impact of the IMS
method, as only cells expressing the targeted cell surface
proteins will be captured by the magnetic beads.
For identification of epithelial-derived cells the epithelial
cell adhesion molecule EpCAM is a commonly used target
[18]. EpCAM is a transmembrane glycoprotein expressed
by both normal and malignant cells of epithelial origin (for
reviews see [19,20]), but over-expressed in many carcino-
mas. In a recent study, EpCAM was shown to be over-
expressed on all breast cancer metastases relative to the
matched primary tumor [21]. Mucin 1 (MUC1), a mem-
brane bound glycosylated phosphoprotein predominantly
expressed by epithelial cells, is suggested to be a marker
for detection of breast-cancer cells not expressing EpCAM
[22]. Mucin 1 is over-expressed in several human malig-
nancies, especially adenocarcinomas (for a review see [23]).
Metastatic tumor cells may also be identified by RT-
PCR which relies on the detection of intracellular gene
transcripts. By carefully selecting genes expressed by the
target tumor cells, but absent from the normal stroma,
this method may allow very sensitive detection of small
metastatic deposits.
The aim of our study was to analyze fresh SLN samples
from early stage breast cancer patients using in sequence,
IMS and RT-PCR techniques for identification of tumor
cells [24]. IMS with anti-EpCAM and anti-Mucin 1 anti-
bodies were used in parallel on disaggregated tissue from
SLN to enrich for cells expressing these epithelial proteins.
The IMS isolated cell fractions were then analyzed by RT-
PCR targeting four epithelial cell associated transcripts;
hMAM, AGR2, SBEM and TFF1. This allowed us to com-
pare findings based on the expression of external cell-
surface proteins (IMS) with those based on intracellular
transcripts (RT-PCR), and to elucidate the molecular het-
erogeneity among the IMS positive cell populations.
Our initial results showed that all RT-PCR positive cells
were also EpCAM positive, indicating that the IMS proce-
dure selected an epithelial cell population. However, only
approximately 50% of all IMS-positive SLN samples
expressed any of the four epithelial transcripts targeted by
our RT-PCR assay. We then speculated that the EpCAM
positive but epithelial transcript negative cells isolated
from the SLNs could be tumor derived cells passing
through an epithelial to mesenchymal transition (EMT).
To investigate this we analyzed more IMS positive SLN
samples using transcripts associated with EMT. This
revealed that EpCAM+ and mammaglobin positive
(hMAM+) cells represented a cell population also
expressing other typical epithelial transcripts. In the
EpCAM+ and hMAM negative cells these epithelial tran-
scripts were lost or markedly reduced, while several
mesenchymal markers were increased. The observed
changes in gene expression were consistent with cells pas-
sing through EMT, indicating that this process could be
important in the lymphatic dissemination of breast cancer.
Materials and methods
Patients and samples
The sentinel nodes used in this study were collected from
January 2008 to March 2010. Patients with primary breast
cancer and clinically negative axillary lymph nodes under-
went sentinel lymph node biopsy (SLNB) and surgery at
Ullevaal University Hospital. The majority of patients had
T1 (≤2 cm) or T2 (> 2 cm ≤5 cm) tumors. In total, 120
SLN samples from as many patients have been analyzed in
this study. The SLNB procedure was performed according
to the guidelines of the Norwegian Breast Cancer Group
[25]. Informed and written consent was obtained from all
patients and the project was approved by the regional
ethics committee. Sentinel lymph nodes from each of the
patients were bisected along the longitudinal axis and one
half was used for routine histopathological assessment.
The other half was used for IMS and RT-PCR analysis.
Immunomagnetic selection method
Antibodies and magnetic beads
The MOC31 (anti-EpCAM) monoclonal antibody (IQ
Products, Groningen, The Netherlands) [26], and BM-7
(from Dr. S. Kaul, Heidelberg, Germany), reacting with the
core protein of Mucin 1, were used in parallel for the
detection and characterization of tumor cells in the disag-
gregated cell suspensions prepared from the sentinel
nodes. Immunomagnetic M450 Dynabeads (Invitrogen,
Oslo, Norway) with a diameter of 4.5 μm and coated with
rat anti-mouse antibodies, were coated with the MOC31
or BM-7 antibodies as previously described [27].
Disaggregation of the sentinel lymph node tissue
The tissue from one half of the lymph node was placed in
a petri dish containing 2 to 5 ml of PBS/1%HSA for disag-
gregation by the use of scalpels. A 70 μm cell strainer
(BD Biosciences, Franklin Lakes, NJ, USA) was placed in a
50 ml tube and the fragmented tissue was filtered through
the cell strainer into the tube. The cell strainer was washed
with PBS/1%HSA. The filtered cell suspension was con-
centrated by centrifugation at 200 g for five minutes and
the cells subsequently resuspended in 5 ml PBS/1%HSA
and transferred to round bottom tubes for incubation with
antibody-coated beads.
Immunomagnetic detection
Each sample was subjected to two different bead-anti-
body combinations, containing either MOC31 or BM-7-
coated immunomagnetic beads, while uncoated beads
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were used for control. Beads were added to the cells in a
ratio of 1:2, and the mixture was incubated under con-
stant rotation for 30 minutes at 4°C in a volume of
1 ml. After incubation, the cells were diluted 1:3 with
PBS/1%HSA and the tubes were placed in a magnet
holder for selection of the cell-immunobead rosettes.
Cells expressing the target antigen were trapped in the
tube by the magnet, whereas the supernatant, containing
unbound cells, was decanted and saved for RNA isola-
tion. The enriched fraction, containing the viable
rosetted cells, was resuspended in 200 μl PBS/1%HSA
and placed on ice. A 20 μl sample of the positively
enriched fraction was pipetted onto a slide and evalu-
ated by microscopy using a Zeiss Axioscope (Carl Zeiss,
Jena, Germany).
Criteria for positivity
A sample was defined as positive when it contained at
least two cells, each with ≥ 5 immunomagnetic beads
bound to its surface, simultaneously evaluating the size,
morphology and three-dimensional picture seen in the
microscope.
RT-PCR analysis
RNA and cDNA synthesis
All RNA extractions were performed using Trizol Reagent
(Invitrogen Life Science, Carlsbad, CA, USA). RNA con-
centration was routinely assessed on the NanoDrop 1000
instrument (Thermo Fisher Scientific, Waltham, MA,
USA). Generally 1 μg of RNA was reverse transcribed
using the qScript cDNA synthesis kit (Quanta BioSciences
Inc., Gaithersburg, MD, USA) in a volume of 20 μl, then
diluted to 50 μl using dH2O. The positive enriched frac-
tions contain few cells and thus have low RNA counts.
RNA from these fractions was not measured, and all avail-
able RNA was loaded into the 20 μl RT-synthesis reaction
and diluted to 30 μl before PCR.
Positive controls for RT-PCR
Mononuclear cells isolated from fresh bone marrow of a
healthy donor were spiked with either SKBR3 or T47d
cells in known ratios (1 SkBr3/104 MNC and 1 T47d/103
MNC). RNA was isolated using Trizol Reagent, dissolved
in RNA storage solution (AM7000, Ambion/Applied Bio-
systems, Austin, TX, USA) and kept as frozen aliquots at
-80°C. The final RNA preparation contained the equiva-
lent of 100 SkBr3 cells/ug and 500 T47d cells/ug, and
based on this each positive control PCR contained the
equivalent of either 10 SkBr3 cells or 50 T47d cells. The
T47d control was a positive control for AGR2 and TFF1
while the SkBR3 control was used for hMAM and SBEM.
Controls were included on all PCR plates for quality
assessment, and for relative quantification purposes. We
used spiked samples and not pure cell lines to closer
mimic the actual clinical samples.
Real-time PCR
Real-time PCR reactions were performed on the iCycler
instrument from BioRad (Hercules, CA, USA). All reac-
tions were run in parallel, and all samples were in 25 μl
volume. Each primer mix contained 200 nM FAM-labeled
probe, 300 nM of each primer and 1x Perfecta qPCR
Supermix (Quanta BioSciences Inc.). Expression of YARS,
a t-RNA synthetase, was used for sample validation and
normalization of expression. The reference gene (YARS)
had been tested in a panel of SLN samples and found to
have equal expression per ng of cDNA. All primers have
been validated using appropriate controls and negative
and positive controls for all targets were always included
in all PCR runs. Primers are designed using the probe fin-
der software from Roche Applied Science available online
at the Universal ProbeLibrary Assay Design Center [28],
and all probes are from the Universal ProbeLibrary collec-
tion (Roche Applied Science). Primer sequences are listed
in Additional file 1.
Criteria for positivity
The four markers hMAM, AGR2, TFF1 and SBEM were
tested and found completely negative in normal bone mar-
row; therefore, no cut-offs were used on the cycle thresh-
old (Ct) values. Only samples which showed positive
signals from the reference gene YARS in both parallels
were considered successfully analyzed. To count as a posi-
tive sample at least one other marker (either hMAM;
AGR2, TFF1 or SBEM) in at least one cell fraction would
have to be positive in both parallels.
EMT RT-PCR arrays
Since our RT-PCR results showed no differences between
EpCAM-positive and Mucin 1 positive cells, we only used
EpCAM positive and EpCAM depleted cell fractions in
the array tests. RNA from EpCAM positive SLN fractions
were first analyzed for YARS and hMAM expression
using our own primers. All RNA was DNase-treated
(Ambion, Austin, TX, USA). Samples denoted by num-
bers (for example, 540+ and 540-) represent EpCAM
positive and depleted cells from single SLN samples.
These were analyzed using approximately 500 ng DNase
treated RNA per array. In order to obtain a higher
amount DNase treated RNA before cDNA synthesis,
some samples were pooled according to hMAM expres-
sion (details of samples are presented in the supplemen-
tary data). These are denoted by letters, for example, G+,
L+, A+, Q+, P+, K- and C- on the arrays, and were ana-
lyzed using 2.5 μg DNase treated RNA per array. Both
quantities are within the range recommended by the
manufacturer. The cDNA was mixed with Perfecta
SYBRGreen supermix (Quanta BioSciences Inc.) and
applied on to ready bought 96-well plates containing pri-
mers for EMT-associated genes (SABiosciences, Freder-
ick, MD, USA). The samples were run on the iCycler
Tveito et al. Breast Cancer Research 2011, 13:R75
http://breast-cancer-research.com/content/13/4/R75
Page 3 of 16
instrument from BioRad using the recommended
protocol.
Data analysis
All expression data were analyzed using the software
GenEx (MultiD analyses AB, Gothenburg, Sweden). The
software includes an application (Normfinder), which
determines the best reference gene(s) for normalization of
expression data. The arrays contained five possible refer-
ence genes, ACTB, GAPDH, B2M, HPRT1 or RPL13A,
and Normfinder determined ACTB and RPL13A to be the
best references in our dataset. We also tried alternative
normalization strategies, but this did not alter the results.
The relative expression of target genes was calculated by
comparing all samples against the average expression of
each gene (Mean log expression = 1). This is an applica-
tion included in the GenEx software.
Statistical analysis
Statistical analysis and hierarchical clustering was also per-
formed using the GenEx software. Two-tailed unpaired t-
tests were used to compare array results obtained from all
EpCAM+ fractions, EpCAM+/hMAM+ or EpCAM
+/hMAM- fractions to results obtained from EpCAM
depleted cell fractions. When genes failed the Kolomo-
gorov-Smirnov test (used to determine if samples show a
normal distribution) a non-parametric Mann-Whitney test
was used to calculate P-values. A P-value ≤0.05 was con-
sidered statistically significant.
Validation of array-results
Real-time RT-PCR for EpCAM, EGFR, Wnt5b, SPARC,
Col1A2, MMP2, ERRB2, hMAM and YARS were per-
formed as previously described for other RT-PCR targets,
but due to low amount of template all reactions were run
as singles. YARS was used for normalization and fold
change was calculated relative to the average expression of
each gene. All calculations and statistics were performed
using the GenEx software. Primer sequences are listed in
Additional file 1
Results
hMAM, AGR2, TFF1 and SBEM were selected for RT-PCR
studies
For detection of breast cancer cells in lymph nodes we
searched the literature for transcripts reported to be either
breast or epithelial associated. We examined the expres-
sion of several potential markers in a panel of 18 normal
bone marrow samples, 6 breast cancer cell lines and 8 cell
lines of other human malignancies. The four genes
hMAM (mammaglobin, MGB1, SCGB2A2) [29], AGR2
(anterior gradient homolog 2) [30], TFF1 (trefoil factor 1,
pS2) [31] and SBEM (small breast epithelial mucin) [32]
were all found negative in bone marrow, indicating their
absence in normal hematopoietic tissue. hMAM proved to
be the most breast specific marker, although its expression
was restricted to only four of six breast cancer cell lines.
TFF1, AGR2 and SBEM were expressed to a varying
degree in all breast cancer cell lines, but also in other
malignancies (Table 1).
Comparison of IMS and RT-PCR results
To elucidate the sensitivity and specificity of the IMS
method we performed, in sequence, IMS screening and
RT-PCR analysis of clinical SLN samples. The IMS assay
employed two antibodies against cell surface markers,
MOC31 (anti-EpCAM) and BM-7 (anti-Mucin 1) for cell
separation. Both immunomagnetically selected cells and
their corresponding depleted fractions, that is, the remain-
ing cell population after positive selection, were collected
and subjected to RT-PCR using the four selected tran-
scripts as molecular markers. The control fraction, corre-
sponding to the original, non-separated cell population,
was also analyzed. A schematic view of the IMS and RT-
PCR procedure is presented in Figure 1.
Each lymph node sample gave a maximum of five cell
fractions for RT-PCR, and from a total of 71 patients we
successfully obtained both IMS and RT-PCR data.
All 71 SLNs were IMS positive with the MOC31 anti-
body, and 53 of these were also positive with BM-7. To
check for associations between IMS and RT-PCR results,
we compared the RT-PCR findings with the IMS data
(Table 2).
Table 1 Expression of hMAM, AGR2, TFF1 and SBEM
measured by RT-PCR
Cell line hMAM AGR2 TFF1 SBEM
T47d + + + +
PM1 + + + +
SKBR-3 + + + +
MCF7 + + + +
MDA-MB231 - + + +
MA11 - + + +
FEM-XI + - - -
SKMEL 28 - - - +
HTB-182 + + + +
786-O - + + -
D54MG - + - -
HT-29 - + + -
T84 - + + -
WiDr - + + -
HuFib - - - -
18 Norm. BM - - - -
Expression of the four epithelial transcripts hMAM, AGR2, TFF1 and SBEM was
evaluated in selected cell lines and healthy bone marrow by RT-PCR.
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Figure 1 Schematic overview of the combined IMS and RT-PCR analysis. 1) Fresh lymph nodes were disintegrated in sterile PBS. The
resulting cell suspension was filtered, centrifuged, diluted in PBS and aliquoted. The cells were then mixed with either MOC31 coated magnetic
beads (anti-EpCAM), BM-7 coated magnetic beads (anti-Mucin 1) or beads without antibodies for control. 2) The cells and beads were incubated
at 4°C for 30 minutes, and placed on a magnet for cell separation. Cells positive for either MOC31 or BM-7 were retained by the magnet while
the negative cells were decanted off into separate tubes. 3) All cell fractions were subjected to individual RNA isolation and RT-PCR analysis. One
patient sample could thus yield a maximum of five different cell fractions for RT-PCR. IMS positive fractions were analyzed for three PCR targets
while the much larger negative fractions were analyzed using five targets.
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Surprisingly, the RT-PCR positive and negative sam-
ples were evenly distributed regardless of which surface
marker they were related to. Of the 71 sentinel lymph
nodes with EpCAM positive cells, 35 were RT-PCR
positive and 36 were negative. Similarly, of 53 Mucin 1
positive samples 27 (51%) were RT-PCR positive.
We then compared the number of IMS positive cells
(based on microscopy inspection of 1/10 of the sam-
ple) detected in each sample to the RT-PCR results
(Table 3). For simplicity, only results obtained from
the MOC31 IMS were used. The numbers varied
greatly from only four positive rosettes in one aliquot
to > 500 positive rosettes in one aliquot. However, the
35 RT-PCR positive samples and the 36 RT-PCR nega-
tive samples did not show any difference with respect
to the number of IMS-positive cells detected (P =
0.48).
EpCAM and Mucin 1 immunomagnetic selection enriched
for RT-PCR marker expressing cells
To further examine the relationship between IMS and
RT-PCR positivity we performed a comparison of RNA
marker expression in the different IMS-defined cell
fractions. In 15 of the 35 RT-PCR positive SLN sam-
ples all five available cell fractions were analyzed by
PCR, and in these the highest RT-PCR marker expres-
sion levels was found in the EpCAM and Mucin 1
positively selected fractions. The remaining cell popu-
lations were clearly depleted of RT-PCR marker
expressing cells, proving that the IMS did select cells
with an epithelial expression profile. RT-PCR signals
from Mucin 1+ or EpCAM+ cells isolated from the
same SLN were similar in all samples, indicating that
the two immunomagnetically selected cell fractions
were identical with respect to expression of the four
chosen RNA markers. Results from representative
patient samples are shown in Figure 2.
hMAM, AGR2, TFF1 and SBEM were expressed by the
same cell population
Of the 35 RT-PCR positive samples, as many as 31 (88%)
showed hMAM expression, making it the most fre-
quently expressed marker. In five cases hMAM was the
only transcript detected. Of the four hMAM negative
samples three were positive for AGR2 and either TFF1,
SBEM or both, whereas the fourth was only positive for
SBEM. A total of 34 of the 35 (97%) positive samples
would have been identified using only hMAM and
AGR2. The data demonstrate that our RT-PCR markers
closely identified the same cell population.
A population of EpCAM positive cells identified in the
lymph nodes lack typical epithelial transcripts
Approximately 50% of the IMS-positive samples showed
no expression of the breast/epithelial specific transcripts,
regardless of the number of IMS positive cells detected in
the samples (Tables 2 and 3). This discrepancy might be
explained if the antibodies employed for IMS bind also to
subpopulations of normal cells in the SLN, or alterna-
tively if a large group of tumor cells do not express the
epithelial RT-PCR markers. As shown in Figure 2 the
immunomagnetic selection of EpCAM or Mucin 1 posi-
tive cells enriched for RT-PCR transcript expressing cells,
demonstrating that all RT-PCR positive cells were
EpCAM positive, but not vice versa. To further investi-
gate this we extended the RT-PCR studies by the use of
pathway-focused PCR-array plates, and tested for tran-
scripts associated with the process of epithelial to
mesenchymal transition. EMT is naturally occurring dur-
ing embryonic development, and is believed to be reacti-
vated in carcinoma metastasis [33-36]. Epithelial cells
undergoing EMT down regulate typical epithelial mar-
kers and become mesenchymal-appearing cells with an
increased capability for motility and invasion of sur-
rounding tissues. If a similar process occurs in breast
cancer cells that migrate to lymph nodes this would have
affected the expression of epithelial transcripts including
those we used in our RT-PCR assay.
A total of 17 IMS isolated samples representing
EpCAM positive or EpCAM depleted cell fractions from
SLNs were successfully analyzed on 96-well PCR-array
plates. Prior to array analysis we scored all samples for
hMAM expression. Information regarding the number
of bead-rosetted cells and hMAM status of each sample
is presented in the Additional file 2. To further examine
Table 2 Comparison of IMS and RT-PCR results
IMS results RT-PCR + RT-PCR ÷ Total
MOC31 + 35 (49%) 36 (51%) 71
MOC31 ÷ - - -
BM7 + 27 (51%) 26 (49%) 53
BM7 ÷ 8 (44%) 10 (56%) 18
The RT-PCR results (positive/negative) are shown as number (%) of the total
samples that were positive or negative with each of the antibodies used in
the immunomagnetic selection (IMS).
Table 3 EpCAM positive cells in RT-PCR positive and RT-PCR negative samples
RT-PCR positive samples RT-PCR negative samples
Lowest # of IMS+ cells Highest # of IMS+ cells Mean # IMS+/sample Lowest # of IMS+ cells Highest # IMS+ cells Mean # IMS+/sample
4 > 500 97 3 245 79
The number of cells positive by immunomagnetic selection (IMS) in one-tenth of the SLN sample is shown in comparison to the final RT-PCR result.
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Figure 2 EpCAM and Mucin 1 enrichment also enriched for cells expressing epithelial transcripts. Cells from SLN samples were separated
by IMS and the resulting cell fractions were analyzed by RT-PCR. Examples from three different RT-PCR positive SLN samples are shown. In all
graphs, the first fraction corresponds to the MOC31 (anti-EpCAM) enriched cell population, that is, all cells which expressed the surface antigen
EpCAM. The next fraction is the MOC31 depleted cells, that is, cells which did not express EpCAM. These are followed by Mucin 1 expressing
cells (BM-7 positive), Mucin 1-depleted cells, and finally the control fraction corresponding to the non-separated cell population of the SLN
sample. Due to the low amounts of template, all IMS enriched fractions were only analyzed for two PCR targets, while depleted- and control
fractions were analyzed using all targets. SBEM was analyzed separately, and was positive in all three samples (not shown). The reference gene
YARS was used for normalization of RT-PCR values and fold change was calculated relative to a positive control included on all PCR plates.
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how the patient samples differed based on expression of
the EMT associated genes we first performed an unsu-
pervised hierarchical clustering analysis of the normal-
ized expression data (Figure 3). This divided all samples
into two major groups, the EpCAM positive cells
(10 arrays) and the EpCAM depleted cells (7 arrays).
The group consisting of EpCAM positive cells was
further split into two clusters, one containing the
EpCAM+/hMAM- cells (five arrays) and one containing
the EpCAM+/hMAM+ cells (five arrays).
We then performed statistical t-tests on array results
obtained from the different groups, that is, we compared
EpCAM+/hMAM+ (5 arrays) vs EpCAM+/hMAM- (5
arrays), EpCAM+ (10 arrays) vs EpCAM depleted cells (7
arrays), and EpCAM+/hMAM- (5 arrays) vs EpCAM
depleted (7 arrays). The low number of samples present in
each group reduces the power of statistical testing, but the
resulting gene lists are useful for evaluating trends in the
data. All results from the t-tests are available in Additional
file 2.
Epithelial transcripts are associated with hMAM
expressing cells
When comparing EpCAM+/hMAM+ cells with EpCAM
+/hMAM- cells the array results revealed that cells
expressing mammaglobin also expressed high levels of
other known epithelial markers such as E-cadherin
(CDH1), epithelial cytokeratins (KRT19 and KRT7), and
desmoplakin (DSP). This confirmed the epithelial nature
of these EpCAM+/hMAM+ cells, and was in agreement
with our initial findings from the RT-PCR-assay where
the use of four epithelial markers gave little additional
information compared to the use of hMAM alone. All
epithelial transcripts seem to be expressed by the same
population of EpCAM+ cells. The estrogen receptor
(ESR1) and ERBB3 (a member of the ErbB family) were
also significantly higher expressed in EpCAM+/hMAM+
compared with EpCAM+/hMAM- cells (Figure 4a). In
contrast, the EpCAM+/hMAM- cells showed a marked
decrease in E-cadherin expression, and no expression of
KRT7 or KRT19, but an increased expression of the
transcription factor Snai2 (Slug), a known repressor of
E-cadherin, the mesenchymal filament vimentin and
Wnt 5B, a component of the Wnt signaling pathway
(Figure 4b).
EMT is characterized by a down-regulation in epithelial
markers, particularly E-cadherin, and an up-regulation of
mesenchymal markers, particularly vimentin. These find-
ings are thus consistent with the EpCAM+/hMAM- cells
being in an EMT-state.
Figure 3 Hierarchical clustering of RT-PCR array data separates cells isolated from SLNs into three groups. cDNA from a total of 17
different samples, representing both EpCAM positive and EpCAM depleted cell fractions, were analyzed on RT-PCR arrays targeting transcripts
associated with EMT. Expression data from the arrays were analyzed using the software GenEX. The hierarchical clustering analysis separated the
samples into three groups: EpCAM+/hMAM+ cells, EpCAM+/hMAM- cells and EpCAM depleted cells.
Tveito et al. Breast Cancer Research 2011, 13:R75
http://breast-cancer-research.com/content/13/4/R75
Page 8 of 16
Transcripts associated with EpCAM enrichment
A number of targets present on the EMT array showed
significantly increased expression in all EpCAM enriched
cell populations compared with the EpCAM depleted cell
fractions. This applied to SPARC, an indirect repressor of
E-cadherin implicated in cellular invasion and motility (for
a recent review see [37]), the transcription factor MITF,
and the epidermal growth factor EGFR. EGFR belongs to
the ErbB family of receptor tyrosine kinases (which also
includes ERBB2 and ERBB3) and members of this family
have been implicated both in EMT induction, and in
tumor progression. Members of the family of metallopro-
teinases (MMP2/3/9), which are matrix degrading
enzymes, collagens (Col1A2, Col3A1) and desmocollin
(DSC2), a protein important for the formation of desmo-
somes and primarily found in epithelial cells, were
also enriched for in all EpCAM positive cell fractions
(Figure 5).
That so many genes were co-expressed with EpCAM,
regardless of hMAM status, confirms that the EpCAM+
cells represented a distinct cell population, different
from the EpCAM depleted cells.
A B
Figure 4 Expression results from 10 EMT arrays representing only EpCAM+ cell populations. The first five samples (G+, L+; 544+, A+ and
517+) also expressed hMAM while the last five (546+, 540+, 542+, P+ and Q+) were negative for hMAM as determined by RT-PCR. Fold changes
were calculated relative to the average expression of each gene. a) All hMAM expressing cell populations co-expressed other epithelial
transcripts as E-cadherin (CDH1), desmoplakin (DSP), and cytokeratins 7 and 19 (KRT7/19). The estrogen receptor (ESR1) and ERBB3 (HER3) were
also expressed mainly by hMAM positive cells. b) In contrast, EpCAM+/hMAM- cells show increased expression of EMT markers; the E-cadherin
repressor Snai2, the mesenchymal filament vimentin (Vim) and Wnt5B, a member of the wnt-signaling pathway, were all increased in EpCAM
+/hMAM- compared with EpCAM+/hMAM+ cell populations.
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Figure 5 EpCAM enrichment by IMS enriched for cells expressing transcripts associated with EMT. All graphs show expression results
from 17 EMT arrays representing EpCAM+/hMAM+ cells (first five arrays), EpCAM+/hMAM- cells (next five arrays) and EpCAM depleted cells (last
seven arrays). Several transcripts were significantly higher expressed in all EpCAM+ fractions compared with the EpCAM depleted cells. This
applied to EGFR, MITF and SPARC (upper panel), members of the metalloproteinase family (middle panel), collagens Col1A2 and Col3A1 and
desmocollin (DSC2, lower panel). Note: sample G+ expressed more EGFR (actual value 419), but this is shortened to fit in the graph. Fold change
is calculated relative to the average expression of each gene.
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Validation of array-results
To validate the results from the RT-PCR array analysis
we selected some genes identified as “EpCAM associated”
and designed our own RT-PCR assays specific for EGFR,
Wnt5b, SPARC, MMP2, and Col1A2. RT-PCR primers
for EpCAM, ERBB2, and hMAM were also included in
this panel. The selected assays were used to analyze 17
new SLN samples, all sorted by IMS into EpCAM
enriched and EpCAM depleted cell populations.
All the selected transcripts showed significantly higher
expression (P ≤0.05) in the EpCAM enriched cell popula-
tions compared with the EpCAM depleted cells, thereby
confirming the array-data. This also applied to EpCAM
itself, as measured by RT-PCR. However, EpCAM expres-
sion was markedly higher in the eight samples also positive
for mammaglobin (EpCAM +/hMAM+) than in the nine
samples not expressing hMAM (Figure 6). In a t-test,
EpCAM was the gene with the single largest mean differ-
ence between groups, both when all EpCAM+ and
EpCAM depleted cells were compared (difference 9.28),
and also when comparing EpCAM+/hMAM+ (difference
10.78) or EpCAM+/hMAM- (difference 7.94) to the
EpCAM depleted cells. This confirms that the IMS-enrich-
ment using MOC31 targets EpCAM-RNA expressing cells.
EGFR, SPARC and Wnt5B were the genes showing the
largest difference between EpCAM+ and EpCAM depleted
cells. SPARC was slightly higher in the EpCAM+/hMAM-
cells, while Wnt5B and EGFR were evenly expressed by all
EpCAM+ cell populations (Figure 7).
Discussion
In early stage breast cancer it is well established that the
metastatic status of the SLN is an important prognostic
parameter, but an optimal method of SLN analysis is still
not available. In this study we sought to compare two
sensitive methods that both seek to identify tumor cells
in sentinel lymph nodes, immunomagnetic selection
(IMS) using antibodies targeting the epithelial surface
proteins EpCAM and Mucin 1, and RT-PCR targeting
breast-epithelial transcripts. The objective was to exam-
ine to what extent the results obtained with the different
methods did overlap and if one method was better than
the other. Our results showed that all RT-PCR positive
cells were EpCAM positive, but the EpCAM-IMS assay
identified twice as many positive specimens as RT-PCR
targeting epithelial transcripts.
When we investigated gene expression using other
RT-PCR markers we found expression profiles consis-
tent with the EpCAM positive but epithelial transcript
negative cells (EpCAM+/hMAM-) being tumor derived
cells passing through an epithelial to mesenchymal tran-
sition (EMT). EMT is a developmental program used in
cell differentiation during embryogenesis, but parts of
this genetic program is believed to be reactivated during
metastasis in order to transform malignant epithelial
cells into motile and invasive mesenchymal-like cells
[33,34,38]. EMT initiates changes in gene transcription
which allows epithelial cells to lose polarity and cell-cell
contact, detach from the epithelial cell layer, modify the
extracellular matrix and migrate through tissues. It is
believed that EMT is a transient state and that the pro-
cess is reversed once the cells form a metastatic lesion.
However, as EMT or EMT-like mechanisms affect gene
expression and protein translation, identifying metastatic
cells while they are en route to a secondary organ might
require different biological markers than the markers
used to identify cells in the primary tumors.
The challenge in micrometastasis detection consists of
identifying very few tumor cells in a background of normal
cells. However, tumor cells that pass through EMT adopt
the phenotypic features of mesenchymal tissue, thereby
making them difficult to distinguish from the surrounding
stroma. Lymph nodes are home to a variety of different
cell populations, many of which have a mesenchymal char-
acter. Consequently, clear evidence of oncogenic EMT is
hard to prove in samples of lymph node tissue. In addi-
tion, genes are rarely implicated in only one cellular pro-
cess; their effects may be quite different depending on the
context in which they are expressed. Thus, we cannot at
present be sure whether we are actually observing cancer
cells passing through EMT or cells involved in other dif-
ferentiation processes. However, a number of indications
point to these cells being tumor derived. First, all cells
were selected by EpCAM protein expression on the cell
surface. The efficiency of this enrichment is demonstrated
by EpCAM RT-PCR results from MOC31 enriched and
depleted cell fractions (Figure 6). EpCAM is a cell surface
protein generally used as an epithelial specific antigen.
Second, our EpCAM-IMS assay proved to enrich for
epithelial-transcript expressing cells as demonstrated both
by our initial RT-PCR assay targeting four epithelial tran-
scripts (Figure 2) and the array results (Figure 4a). Third,
all EpCAM positive cells consistently showed increased
expression of a number of transcripts compared with the
EpCAM depleted cells, demonstrating that EpCAM posi-
tive cells represent a distinct cell population independent
of hMAM expression. Some genes were nearly exclusively
expressed by EpCAM positive cells (EGFR, Serpine-1
(PAI-1), Snai2, Col3A1 and MMP2/3), while others were
enriched for (SPARC, MITF, MMP9, MST1R Col1A2/
Col5A2, Wnt5A/Wnt5B and others). This expression pat-
tern was confirmed for some selected genes using different
RT-PCR primers and a new set of SLN samples (Figure 7).
Fourth, the changes in expression observed between
EpCAM+/hMAM+ and EpCAM+/hMAM- cell popula-
tions were consistent with changes expected to occur dur-
ing EMT (Figure 4a, b). Thus, as expression of E-cadherin
and other epithelial transcripts were lost or greatly
Tveito et al. Breast Cancer Research 2011, 13:R75
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Figure 6 EpCAM-IMS enriched for EpCAM RNA expressing cells. EpCAM expression was significantly increased in EpCAM-IMS enriched cell
populations compared with the corresponding EpCAM depleted cell fraction. This applied to both EpCAM+/hMAM+ cell populations (upper
panel) and to EpCAM+/hMAM- cell populations (lower panel). Note that the scale is different, reflecting the generally lower expression level of
EpCAM in EpCAM+/hMAM- cells compared with the EpCAM+/hMAM+ populations. To fit the graphs the value for sample 552+ has been set to
200 (actual value 605), while 555+ has been set to 50 (actual value 70). Fold change is calculated relative to the average expression of EpCAM in
all samples.
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reduced, mesenchymal markers as Snai2 (Slug), vimentin,
Wnt5B, and MMP9 were increased. Collectively these
results indicate that EpCAM+/hMAM- cells are tumor-
derived cells similar to EpCAM+/hMAM+ cells, but with
phenotypic alterations compatible with an EMT state.
Epithelial cytokeratins are commonly used for antibody-
based detection of tumor deposits in SLN by immunohis-
tochemistry (IHC). Recently, both hMAM and CK19 also
received FDA approval as markers for the RT-PCR based
analysis of SLNs in a diagnostic kit (GeneSearch Breast
Lymph Node (BLN) assay; Veridex LLC, Raritan, NJ,
USA). Studies that have compared RT-PCR and IHC on
SLN samples generally find that the methods agree
[39-41], demonstrating that epithelial protein- and RNA-
markers are expressed by the same cells. As shown in
Figure 4a our EpCAM+/hMAM+ cells also expressed
CK19, along with other epithelial markers. However,
hMAM is not a universal marker of breast cancer derived
tumor cells, as demonstrated by our initial test where only
four of six breast cancer cell lines were found to express
hMAM. Similarly, the expression of different cytokeratins
has been found to vary considerably in DTC detected in
bone marrow from breast cancer patients [42]. As our
EpCAM IMS assay detected both hMAM +/- cells and CK
+/- cells, this demonstrates that EpCAM is able to capture
a broader range of tumor cells. Importantly, these
mesenchymal-like cells will remain undetected when
purely epithelial markers are used.
All patients included in this study were early stage,
clinically node-negative patients. Statistically, the
expected five-year survival rate is between 85 and 95%
(based on T1/T2 patients, prognoses from [43]). Our
EpCAM IMS assay therefore detects cells in SLNs of far
more patients than those who can be expected to suffer
from relapse later. However, although these cells have
migrated to the lymph node we do not know whether
they will spread further from there. Currently, it is not
known which characteristics that identify metastatic
founder cells or which factors that influence the fate of
cells disseminated to lymph nodes. Emerging evidence
from studies on bone marrow suggests that tumor cell
dissemination is a common event which starts at an early
stage, and that disseminated cells may evolve at the ecto-
pic site independently of the primary tumor [44,45]. We
do not know what potential cells disseminated to lymph
nodes have to give rise to distant metastases, but the data
are relevant in the context of understanding tumor cell
dissemination and behavior.
Figure 7 EpCAM-IMS enriched cell populations are also enriched for EGFR, Wnt5B and SPARC RNA expression. RT-PCR analysis targeting
EGFR, Wnt5B and SPARC all showed increased expression of these transcripts in EpCAM enriched cell populations compared with the
corresponding EpCAM depleted cell populations (separated by IMS). This was true in SLN samples with hMAM expression (first eight samples;
SLN 532 to 556) and in SLN samples negative for hMAM (last nine samples, SLN 530 to 554). Fold change was calculated relative to the average
expression of each gene.
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Antibodies targeting EpCAM are commonly used for
detecting metastatic cells in blood or bone marrow
[46-48]. Notably, EpCAM is approved for diagnostic use
in the CellSearch assay which aims to detect circulating
breast cancer cells [49-51]. It has been suggested that
EpCAM might be down-regulated as a consequence of
EMT [52,53]. However, our data indicate the concomitant
expression of EpCAM and EMT markers on metastatic
cells in SLNs, in line with recent results obtained on sam-
ples from bone marrow [54] and blood [55]
Our EpCAM RT-PCR assay consistently showed higher
EpCAM expression in EpCAM+/hMAM+ samples than in
EpCAM+/hMAM- samples (Figure 6). This difference did
not reflect results obtained in the EpCAM IMS assay
where many samples later found to be hMAM negative
contained high numbers (> 1,000) of heavily MOC31-
rosetted cells. This apparent imbalance in EpCAM protein
expression and RNA expression could reflect the dynamics
of an EMT process, where the halt of mRNA transcription
and degradation of mRNA transcripts might be more
rapidly executed than the internalization and degradation
of proteins already present in the cell membrane. Thus, in
cells undergoing EMT, proteins associated with an epithe-
lial profile could be detectable longer than the transcripts
encoding them.
Breast cancer is a very heterogeneous disease with varia-
tion both on the DNA, RNA and protein levels [56,57].
This heterogeneity is found within tumors as well as
between patients, and can be explained by several mechan-
isms; the origin of the cell causing the cancer [58], the dif-
ferent environmental factors involved in driving the
tumor, and transient changes in cellular status associated
with malignant progression, such as EMT [33-35,38,59].
We observed a large heterogeneity on the RNA level
among our EpCAM enriched cell populations, also in
hMAM expression. Since our RT-PCR results are based
on the pool of EpCAM positive cells, it can not be derived
from this whether the variable hMAM intensity was due
to a difference between patients, or if patients with low
hMAM expression had a mixture of EpCAM+/hMAM+
and EpCAM+/hMAM- cells. EMT is a plastic process and
the transition from an epithelial cell to a mesenchymal-
like cell is probably a continuum rather than an abrupt
change. Thus, it will be interesting to analyze EpCAM
positive cells at the single cell level to see if such differ-
ences in cell state are detectable within individual patients.
Conclusions
Our analysis of SLN samples indicates that the activa-
tion of EMT like processes is important in the lympha-
tic dissemination of breast cancer. EpCAM thus appear
to be a more universal marker of breast cancer micro-
metastasis than pure epithelial derived targets, as it will
also detect tumor cells with EMT-like characteristics.
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